Abstract
Neutrophil migration is a key host event against infection. Chemotherapy may alter neutrophil function and favor increased risk of infection. Herein, we investigated the effect of chemotherapy on the migration capacity of circulating neutrophils obtained from breast cancer patients and mechanisms involved in this event. Breast cancer women (n=23) at disease stage I–III and healthy control women (n=25) were prospectively enrolled. No differences in the in vitro migratory responses towards the chemotactic stimuli N-formyl- L-methionyl- L-leucyl- L-phenylalanine (fMLP), leukotriene B4 (LTB4) and interleukin (IL)-8 were observed in purified neutrophils from controls and patients, in a microchemotaxis chamber assay. However, the migration capacity evaluated upon chemotherapy (5-fluoruracil, adriamycin and cyclophosphamide, 21-day intervals between cycles, total leukocyte count ≥2,000/mm3), on the day immediately before the beginning of the sixth cycle, showed that patient neutrophils (n=14) failed to migrate in response to fMLP compared to response observed upon diagnosis. Considering patients (n=8) with documented bacterial infection between cycles, the number of migrated neutrophils (mean±SD) compared to response at diagnosis was markedly reduced upon chemotherapy to either fMLP (30.1±8.26 vs. 2.81±1.28) or LTB4 (15.72±4.8 vs. 2.8±1.64) stimuli respectively. Treatment of control neutrophils with sera of chemotherapy-treated patients with infective episodes, to test for the presence of circulating immunosuppressive factors, significantly reduced the migratory capacity of healthy neutrophils to fMLP, LTB4 and IL-8, in a dose-dependent way. But no significant differences were found in the serum levels of nitric oxide (NO) metabolites, tumor necrosis factor (TNF)-α, IL-6, IL-8 and IL-10 collected at the same time as the collection of blood for neutrophil migration experiments. In conclusion, breast cancer patients showed suppressed neutrophil migratory response upon chemotherapy, accompanied by bacterial infection episodes. Circulating factors are involved, at least partially, in the inhibitory mechanism on neutrophil migration.
Similar content being viewed by others
References
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow?. Lancet 357:539–545
Bokoch GM (1995) Chemoattractant signaling and leukocyte activation. Blood 86:1649–1660
Moser B, Wolf M, Walz A, Loetscher P (2004) Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25:75–84
Malawista SE, Montgomery RR, van Blaricom G (1992) Evidence for reactive nitrogen intermediates in killing of staphylococci by human neutrophil cytoplasts. A new microbicidal pathway for polymorphonuclear leukocytes. J Clin Invest 90:631–636
Fierro IM, Nascimento-DaSilva V, Arruda MA, Freitas MS, Plotkowski MC, Cunha FQ, Barja-Fidalgo C (1999) Induction of NOS in rat blood PMN: in vivo and in vitro modulation by tyrosine kinase and involvement in bactericidal activity. J Leuk Biol 65:508–514
Tavares-Murta BM, Zaparoli M, Ferreira RB, Silva-Vergara ML, Oliveira CHB, Murta EFC, Ferreira SH, Cunha FQ (2002) Failure of neutrophil chemotactic function in septic patients. Crit Care Med 30:1056–1061
Duignan JP, Collins PB, Johnson AH, Bouchier-Hayes D (1986) The association of impaired neutrophil chemotaxis with postoperative surgical sepsis. Br J Surg 73:238–240
Arii K, Tanimura H, Iwahashi M, Tsunoda T, Tani M, Noguchi K, Mizobata S, Hotta T, Nakamori M, Yamaue H (2000) Neutrophil functions and cytokine production in patients with gastric cancer. Hepatogastroenterol 47:291–297
Elomaa I, Joensuu H, Blomqvist C (2003) Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial. Ann Oncol 14:699–703
Humphreys JM, Stringer RE, Hart CA, Edwards SW (1993) Effect of cytotoxic drugs on mature neutrophil function in the presence and absence of granulocyte-macrophage colony-stimulating factor. Br J Haematol 84:316–321
Lejeune M, Ferster A, Cantinieaux B, Sariban E (1998) Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia. Br J Haematol 102:1284–1291
Amar M, Pham Huu T, Amit N, Hakim J (1993) Molecular mechanisms involved in the inhibition of neutrophil locomotion by tumor cells. Blood Cells 19:177–184
Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S, D’Ambrosio FP (1999) Interleukin-12, interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett 68:355–358
Cope AP, Aderka D, Wallach D, Kahan M, Chu NR, Brennan FM, Feldmann MD (1995) Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 84:21–30
Jablonska E (1998) Serum levels of tumor necrosis factor alpha and production of this cytokine by polymorphonuclear cells in breast cancer patients. Arch Immunol Ther Exp 46:93–96
Coskun U, Gunel N, Onuk E, Yilmaz E, Bayram O, Yamac D, Cihan A, Ucan B, Yildirim Y, Celenkoglu G, Ozkan S (2003) Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer. Neoplasma 50:210–216
Benjamim CF, Ferreira SH, Cunha FQ (2000) Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 182:214–223
Tavares-Murta BM, Machado JS, Ferreira SH, Cunha FQ (2001) Nitric oxide mediates the inhibition of neutrophil migration induced by systemic administration of LPS. Inflammation 25:247–253
Crosara-Alberto DP, Darini AL, Inoue RY, Silva JS, Ferreira SH, Cunha FQ (2002) Involvement of NO in the failure of neutrophil migration in sepsis induced by Staphylococcus aureus. Br J Pharmacol 136:645–658
Glasser L, Fiederlein RL (1990) The effect of various cell separation procedures on assays of neutrophil function. A critical appraisal. Am J Clin Pathol 93:662–669
Lang S, Lauffer L, Clausen C, Lohr I, Schmitt B, Holzel D, Wollenberg B, Gires O, Kastenbauer E, Zeidler R (2003) Impaired monocyte function in cancer patients: restoration with a cyclooxigenase-2 inhibitor. FASEB J 17:286–288
Schimidt HHHW, Wilke P, Evers B, Bohme E (1989) Ezymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem Biophys Res Commun 165:284–291
Green LC, Ruiz de Luzuriaga K, Wagner DA, Rand W, Istfan N, Young VR, Tannenbaum SR (1981) Nitrate biosynthesis in man. Proc Natl Acad Sci USA 78:7764–7768
Lukac J, Lechpammer S, Kusic Z, Bolanca A, Dakovic N (1994) Prognostic significance of phagocytic functions in breast cancer patients. Eur J Cancer 30:2185–2186
Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A (2000) Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res 20:4599–4604
Póka R, Szûcs S, Ádány R, Szikszay E (2000) Stage-related superoxide anion production of granulocytes of gynecologic cancer patients. Eur J Obstet Gynecol Reprod Biol 89:55–57
Azzarà A, Carulli G, Rizzuti-Gullaci A, Minnucci S, Capochiani E, Ambrogi F (1996) Motility of rhG-CSF-induced neutrophils in patients undergoing chemotherapy: evidence for inhibition detected by image analysis. Br J Hematol 92:161–168
Lejeune M, Sariban E, Cantinieaux B, Ferster A, Devalck C, Fondu P (1996) Granulocyte functions in children with cancer are differentially sensitive to the toxic effect of chemotherapy. Pediatr Res 39:835–842
Hartmann P, Herhotz K, Salzberger B, Petereit HF (2004) Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma. Ann Hematol 83: 212–217
Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227
Tavares-Murta BM, Cunha FQ, Ferreira SH (1998) The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production. Br J Pharmacol 124:1369–1374
Janetzki S, Cox JH, Oden N, Ferrari G (2005) Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302:51–86
Mazur B, Mertas A, Sota-Jakimczyk D, Szczepaski T, Janik-Moszant A (2004) Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol Oncol 22:27–34
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94–102
Demirkazik A, Kessinger A, Lynch J, Reed E, Tarantolo S, Sharp JG (2002) Effect of prior therapy and bone marrow metastases on progenitor cell content of blood stem cell harvests in breast cancer patients. Biol Blood Marrow Transplant 8:268–272
Ghio M, Ottonello L, Contini P, Amelotti M, Mazzei C, Indiveri F, Puppo F, Dallegri F (2003) Transforming growth factor-β1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 102:1100–1107
Gainetdinov RR, Bohn LM, Walker JKL, Laporte SA, Macrae AD, Caron MG, Lefkowitz RJ, Premont RT (1999) Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 24:1029–1036
Fan J, Malik AB (2003) Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nature Med 9:315–321
Murta EF, de Andrade JM, Falcao RP, Bighetti S (2000) Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86:403–407
Solomayer EF, Feuerer M, Bai LH, Umansky V, Beckhove P, Meyberg GC, Bastert G, Schirrmacher V, Diel IJ (2003) Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 9:174–180
Acknowledgments
We thank Januário Barbosa dos Santos Júnior, Douglas Cobo Micheli, Eduardo Schmidt Bachin and Lilian Beatriz Davi for technical assistance, Giuliana Bertozzi for cytokine assay and Beatriz Cibele Rezende Gerolin for confection of figures. We also thank the financial support by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mendonça, M.A.O., Cunha, F.Q., Murta, E.F.C. et al. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy. Cancer Chemother Pharmacol 57, 663–670 (2006). https://doi.org/10.1007/s00280-005-0086-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0086-4